Luisa Fernández-Chirino
Research Subjects
Research Interests
Luisa Fernández-Chirino has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
- Omar Yaxmehen Bello-Chavolla
Instituto Nacional de Geriatría, Mexico City, Mexico
22 shared publications - Neftali Eduardo Antonio-Villa
Department of Endocrinology, Instituto Nacional de Cardiología Ignacio Chávez , Mexico City
20 shared publications - Carlos Alberto Fermín-Martínez
Research Division, Instituto Nacional de Geriatría, Mexico City, Mexico
17 shared publications - Arsenio Vargas-Vázquez
Facultad de Medicina, Universidad Nacional Autónoma de México
16 shared publications - Daniel Ramírez-García
Research Division, Instituto Nacional de Geriatría
9 shared publications - Jacqueline A. Seiglie
Diabetes Unit, Massachusetts General Hospital, Harvard Medical School
6 shared publications
Latest Publications
- Open Access
- 10 April 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (12) , 3451-3460
Prediabetes and Risk of All-Cause and Cause-Specific Mortality: A Prospective Study of 114 062 Adults in Mexico City
Background: Prediabetes has been associated with increased all-cause and cardiovascular mortality. However, no large-scale studies have been conducted in Mexico or Latin America examining these associations. Methods: We analyzed data from 114 062 adults without diabetes (diagnosed or undiagnosed) from the Mexico City Prospective Study. Participants were followed until January 1, 2021, for cause-specific mortality. We defined prediabetes according to the American Diabetes Association (ADA; HbA1c ≥ 5.7% to <6.5%) and the International Expert Committee (IEC; HbA1c ≥ 6.0 to <6.5%) definitions. Cox regression adjusted for confounders was used to estimate all-cause and cause-specific mortality rate ratios (RR) for deaths occurring at ages 35 to 74 years associated with prediabetes. Results: After median 18.4 (IQR 17.6-19.7) years of follow-up, individuals with prediabetes had higher risk of all-cause mortality at ages 35 to 74 compared to those without prediabetes (RR 1.13 [1.07-1.20] for ADA-defined and 1.27 [1.17-1.38] for IEC-defined prediabetes), as well as higher risk of cardiovascular (RR 1.23 [1.11-1.37] and 1.44 [1.24-1.67], respectively), renal (RR 1.33 [1.06-1.66] and 1.62 [1.18-2.23], respectively), and acute diabetic deaths (RR 2.62 [1.75-3.93] and 3.42 [2.09-5.61], respectively). The absolute excess risk associated with ADA-defined prediabetes at ages 35 to 74 accounted for 7% of cardiovascular, 9% of renal, and 31% of acute diabetic deaths. IEC-defined prediabetes accounted for 4%, 5% and 14% of cardiovascular, renal, and acute diabetic deaths. Prediabetes-associated excess mortality risks were, at least in part, explained by adiposity. Conclusion: Prediabetes is a significant risk factor for all-cause, cardiovascular, renal, and acute diabetic deaths in Mexican adults. Early identification and timely management of prediabetes among individuals at risk of this condition could reduce premature mortality in this population.
- 10 April 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (12) , 3451-3460
Open AccessPrediabetes and Risk of All-Cause and Cause-Specific Mortality: A Prospective Study of 114 062 Adults in Mexico City
Background: Prediabetes has been associated with increased all-cause and cardiovascular mortality. However, no large-scale studies have been conducted in Mexico or Latin America examining these associations. Methods: We analyzed data from 114 062 adults without diabetes (diagnosed or undiagnosed) from the Mexico City Prospective Study. Participants were followed until January 1, 2021, for cause-specific mortality. We defined prediabetes according to the American Diabetes Association (ADA; HbA1c ≥ 5.7% to <6.5%) and the International Expert Committee (IEC; HbA1c ≥ 6.0 to <6.5%) definitions. Cox regression adjusted for confounders was used to estimate all-cause and cause-specific mortality rate ratios (RR) for deaths occurring at ages 35 to 74 years associated with prediabetes. Results: After median 18.4 (IQR 17.6-19.7) years of follow-up, individuals with prediabetes had higher risk of all-cause mortality at ages 35 to 74 compared to those without prediabetes (RR 1.13 [1.07-1.20] for ADA-defined and 1.27 [1.17-1.38] for IEC-defined prediabetes), as well as higher risk of cardiovascular (RR 1.23 [1.11-1.37] and 1.44 [1.24-1.67], respectively), renal (RR 1.33 [1.06-1.66] and 1.62 [1.18-2.23], respectively), and acute diabetic deaths (RR 2.62 [1.75-3.93] and 3.42 [2.09-5.61], respectively). The absolute excess risk associated with ADA-defined prediabetes at ages 35 to 74 accounted for 7% of cardiovascular, 9% of renal, and 31% of acute diabetic deaths. IEC-defined prediabetes accounted for 4%, 5% and 14% of cardiovascular, renal, and acute diabetic deaths. Prediabetes-associated excess mortality risks were, at least in part, explained by adiposity. Conclusion: Prediabetes is a significant risk factor for all-cause, cardiovascular, renal, and acute diabetic deaths in Mexican adults. Early identification and timely management of prediabetes among individuals at risk of this condition could reduce premature mortality in this population.
- Open Access
- 31 October 2023
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 27, 100624
The evolving landscape of SARS-CoV-2 vaccination in Mexico: real-world evidence in Mexican pensioners
- 31 October 2023
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 27, 100624
Open AccessThe evolving landscape of SARS-CoV-2 vaccination in Mexico: real-world evidence in Mexican pensioners
- Open Access
Smoking, all-cause, and cause-specific mortality in individuals with diabetes in Mexico: an analysis of the Mexico City Prospective Study
BACKGROUND: Evidence from low– and middle-income countries regarding the effect of smoking in people with diabetes is lacking. Here, we report the association of smoking with mortality in a large cohort of Mexican adults with diabetes. METHODS: Participants with diabetes mellitus (self-reported medical diagnosis, use of antidiabetic medications or HbA1c ≥6.5%) aged 35-74 years when recruited into the Mexico City Prospective Study were included. Cox regression confounder-adjusted mortality rate ratios (RRs) associated with baseline smoking status were estimated. FINDINGS: Among 15,975 women and 8225 men aged 35-74 years with diabetes but no other comorbidities at recruitment, 2498 (16%) women and 2875 (35%) men reported former smoking and 2753 (17%) women, and 3796 (46%) men reported current smoking. Smoking less than daily was common: 39.4% of female current smokers and 30.7% of male current smokers. During a median of 17 years of follow-up there were 5087 deaths at ages 35-74 years. Compared with never smoking, the all-cause mortality RR was 1.08 (95%CI 1.01–1.17) for former smoking, 1.09 (95%CI 0.99–1.20) for non-daily smoking, 1.06 (95%CI 0.96–1.16) for smoking st , 2023, using the terms ((diabetes mellitus) OR (type 2 diabetes mellitus)) AND ((smoking) OR (tobacco)) AND ((mortality) OR (survival analysis) OR (death)). We identified a meta-analysis published in 2015 which analysed data from 1,132,700 participants with diabetes from 89 cohort studies. Among current and former smokers, the pooled adjusted relative risk for all-cause mortality was 1.55 (95% CI 1.46–1.64) and 1.19 (95% CI 1.11–1.28), respectively. Among current smokers, there was considerably higher risk of death due to cardiovascular disease, coronary heart disease, stroke, peripheral arterial disease, and heart failure. Most included studies were conducted in high income countries and only one was done in Latin America (Argentina, 1,730 participants). In Mexico, epidemiological studies related to smoking have been primarily descriptive in nature. A previous study of the MCPS that analysed all-cause smoking-related mortality among disease-free individuals found adjusted rate ratios among daily smokers of 1.17 (95% CI 1.10–1.25) for those using <10 cigarettes/day and 1.54 (95% CI 1.42–1.67) for those using ≥10 cigarettes/day. In this study, mortality risk in people with diabetes was not assessed separately. Instead, mortality risk estimates were obtained for several chronic diseases as a group. No other studies have analysed changes in smoking habits and smoking-related mortality in Mexican individuals with diabetes. Added value of this study: To our knowledge, this is the first analysis of longitudinal data of Mexican adults with diabetes (n=24,200) followed over 17 years, to examine the association between smoking and all-cause and cause-specific mortality. Compared with never smokers with diabetes, former and daily smokers with diabetes had elevated mortality. Among daily smokers there was higher risk of death due to cardiovascular disease, acute diabetes complications, lung cancer and COPD. Our results are generally consistent with previous analyses that have found smoking as a significant risk factor for higher mortality in individuals with diabetes. Our estimates, however, are comparably lower for all-cause mortality, possibly related to distinct smoking habits specific to the Mexican population with diabetes. Implications of all available evidence: Our results confirm that smoking is a significant risk factor for all-cause and cause-specific mortality among Mexican adults with diabetes. Strategies to promote smoking cessation among individuals with diabetes should be encouraged, particularly given that tobacco use is a modifiable risk factor. This is especially meaningful in middle-to lower-income countries like Mexico, where diabetes prevalence is increasing and achieving glycaemic targets remains a challenge.
Open AccessSmoking, all-cause, and cause-specific mortality in individuals with diabetes in Mexico: an analysis of the Mexico City Prospective Study
BACKGROUND: Evidence from low– and middle-income countries regarding the effect of smoking in people with diabetes is lacking. Here, we report the association of smoking with mortality in a large cohort of Mexican adults with diabetes. METHODS: Participants with diabetes mellitus (self-reported medical diagnosis, use of antidiabetic medications or HbA1c ≥6.5%) aged 35-74 years when recruited into the Mexico City Prospective Study were included. Cox regression confounder-adjusted mortality rate ratios (RRs) associated with baseline smoking status were estimated. FINDINGS: Among 15,975 women and 8225 men aged 35-74 years with diabetes but no other comorbidities at recruitment, 2498 (16%) women and 2875 (35%) men reported former smoking and 2753 (17%) women, and 3796 (46%) men reported current smoking. Smoking less than daily was common: 39.4% of female current smokers and 30.7% of male current smokers. During a median of 17 years of follow-up there were 5087 deaths at ages 35-74 years. Compared with never smoking, the all-cause mortality RR was 1.08 (95%CI 1.01–1.17) for former smoking, 1.09 (95%CI 0.99–1.20) for non-daily smoking, 1.06 (95%CI 0.96–1.16) for smoking st , 2023, using the terms ((diabetes mellitus) OR (type 2 diabetes mellitus)) AND ((smoking) OR (tobacco)) AND ((mortality) OR (survival analysis) OR (death)). We identified a meta-analysis published in 2015 which analysed data from 1,132,700 participants with diabetes from 89 cohort studies. Among current and former smokers, the pooled adjusted relative risk for all-cause mortality was 1.55 (95% CI 1.46–1.64) and 1.19 (95% CI 1.11–1.28), respectively. Among current smokers, there was considerably higher risk of death due to cardiovascular disease, coronary heart disease, stroke, peripheral arterial disease, and heart failure. Most included studies were conducted in high income countries and only one was done in Latin America (Argentina, 1,730 participants). In Mexico, epidemiological studies related to smoking have been primarily descriptive in nature. A previous study of the MCPS that analysed all-cause smoking-related mortality among disease-free individuals found adjusted rate ratios among daily smokers of 1.17 (95% CI 1.10–1.25) for those using <10 cigarettes/day and 1.54 (95% CI 1.42–1.67) for those using ≥10 cigarettes/day. In this study, mortality risk in people with diabetes was not assessed separately. Instead, mortality risk estimates were obtained for several chronic diseases as a group. No other studies have analysed changes in smoking habits and smoking-related mortality in Mexican individuals with diabetes. Added value of this study: To our knowledge, this is the first analysis of longitudinal data of Mexican adults with diabetes (n=24,200) followed over 17 years, to examine the association between smoking and all-cause and cause-specific mortality. Compared with never smokers with diabetes, former and daily smokers with diabetes had elevated mortality. Among daily smokers there was higher risk of death due to cardiovascular disease, acute diabetes complications, lung cancer and COPD. Our results are generally consistent with previous analyses that have found smoking as a significant risk factor for higher mortality in individuals with diabetes. Our estimates, however, are comparably lower for all-cause mortality, possibly related to distinct smoking habits specific to the Mexican population with diabetes. Implications of all available evidence: Our results confirm that smoking is a significant risk factor for all-cause and cause-specific mortality among Mexican adults with diabetes. Strategies to promote smoking cessation among individuals with diabetes should be encouraged, particularly given that tobacco use is a modifiable risk factor. This is especially meaningful in middle-to lower-income countries like Mexico, where diabetes prevalence is increasing and achieving glycaemic targets remains a challenge.
- Open Access
Nationally representative prevalence and determinants of post-acute sequelae of SARS-CoV-2 infection (Long COVID) amongst Mexican adults in 2022
OBJECTIVE: To characterize the epidemiology of post-acute sequelae after SARS-CoV-2 infection (PASC) in Mexico during 2022 and identify potential predictors of PASC prevalence using nationally representative data. METHODS: We analyzed data from the 2022 Mexican National Health and Nutrition Survey (ENSANUT) totaling 24,434 participants, representing 85,521,661 adults ≥20 years. PASC was defined using both the World Health Organization definition and a PASC score ≥12. Estimates of PASC prevalence were stratified by age, sex, rural vs. urban setting, social lag quartiles, number of reinfections, vaccination status and by periods of predominance of SARS-CoV-2 circulating variants. Predictors of PASC were assessed using logistic regression models adjusted by survey weights. RESULTS: Persistent symptoms after SARS-CoV-2 infection were reported by 12.44% (95%CI 11.89-12.99) of adults ≥20 years in Mexico during 2022. The most common persistent symptoms were musculoskeletal pain, headache, cough, loss of smell or taste, fever, post-exertional malaise, brain fog, anxiety, chest pain, and sleep disorders. PASC was present in 21.21% (95%CI 7.71-9.65) subjects with previously diagnosed COVID-19. Over 28.6% patients with PASC reported symptoms persistence ≥6 months and 14.05% reported incapacitating symptoms. Higher PASC prevalence was associated with SARS-CoV-2 reinfections, depressive symptoms and living in states with high social lag. PASC prevalence, particularly its more severe forms, decreased with COVID-19 vaccination and for infections during periods of Omicron variant predominance. CONCLUSIONS: PASC implies a significant public health burden in Mexico as the COVID-19 pandemic transitions into endemicity. Promoting reinfection prevention and booster vaccination may be useful to reduce PASC burden.
Open AccessNationally representative prevalence and determinants of post-acute sequelae of SARS-CoV-2 infection (Long COVID) amongst Mexican adults in 2022
OBJECTIVE: To characterize the epidemiology of post-acute sequelae after SARS-CoV-2 infection (PASC) in Mexico during 2022 and identify potential predictors of PASC prevalence using nationally representative data. METHODS: We analyzed data from the 2022 Mexican National Health and Nutrition Survey (ENSANUT) totaling 24,434 participants, representing 85,521,661 adults ≥20 years. PASC was defined using both the World Health Organization definition and a PASC score ≥12. Estimates of PASC prevalence were stratified by age, sex, rural vs. urban setting, social lag quartiles, number of reinfections, vaccination status and by periods of predominance of SARS-CoV-2 circulating variants. Predictors of PASC were assessed using logistic regression models adjusted by survey weights. RESULTS: Persistent symptoms after SARS-CoV-2 infection were reported by 12.44% (95%CI 11.89-12.99) of adults ≥20 years in Mexico during 2022. The most common persistent symptoms were musculoskeletal pain, headache, cough, loss of smell or taste, fever, post-exertional malaise, brain fog, anxiety, chest pain, and sleep disorders. PASC was present in 21.21% (95%CI 7.71-9.65) subjects with previously diagnosed COVID-19. Over 28.6% patients with PASC reported symptoms persistence ≥6 months and 14.05% reported incapacitating symptoms. Higher PASC prevalence was associated with SARS-CoV-2 reinfections, depressive symptoms and living in states with high social lag. PASC prevalence, particularly its more severe forms, decreased with COVID-19 vaccination and for infections during periods of Omicron variant predominance. CONCLUSIONS: PASC implies a significant public health burden in Mexico as the COVID-19 pandemic transitions into endemicity. Promoting reinfection prevention and booster vaccination may be useful to reduce PASC burden.
- Open Access
Prevalence of untreated prediabetes and glucose metabolism disturbances in Mexico: An analysis of nationally representative surveys spanning 2016-2021
OBJECTIVE Characterizing prediabetes phenotypes may be useful in guiding diabetes prevention efforts; however, heterogeneous criteria to define prediabetes have led to inconsistent prevalence estimates, particularly in low- and middle-income countries. We estimated trends in untreated prediabetes prevalence in Mexico across different definitions and its association with prevalent cardiometabolic conditions. METHODS We conducted a serial cross-sectional analysis of National Health and Nutrition Surveys in Mexico (2016-2021), totaling 21,442 Mexican adults, excluding individuals with diagnosed or undiagnosed diabetes. Prediabetes was defined using ADA (impaired fasting glucose [IFG] 100-125 mg/dL and/or HbA1c 5.7-6.4%), WHO (IFG 110-125 mg/dL), and IEC criteria (HbA1c 6.0-6.4%). Prevalence trends of prediabetes over time were evaluated using Poisson regression and its association with prevalent cardiometabolic conditions with logistic regression. RESULTS Prevalence of prediabetes in Mexico in 2021 was 27.3%. Despite an overall downward trend in prediabetes (RR 0.960, 95%CI 0.940-0.979), this decrease was primarily driven by decreases in prediabetes by ADA-IFG (RR 0.883, 95%CI 0.861-0.907) and WHO-IFG criteria (RR 0.878, 95%CI 0.838-0.921), while prediabetes by ADA-HbA1c (RR 1.049, 95%CI 1.022-1.077) and IEC-HbA1C criteria (RR 1.064, 95%CI 1.014-1.115) increased over time. Prediabetes prevalence increased over time in adults >40 years, individuals with central obesity, self-identified as indigenous or living in urban areas. Regardless of the definition, prediabetes was associated with increased risk of cardiometabolic conditions. CONCLUSIONS Prediabetes rates in Mexico from 2016-2021 varied based on defining criteria but consistently increased for HbA1c-based definitions and high-risk subgroups. Regardless of the definition, prediabetes clusters subjects with high cardiometabolic risk.
Open AccessPrevalence of untreated prediabetes and glucose metabolism disturbances in Mexico: An analysis of nationally representative surveys spanning 2016-2021
OBJECTIVE Characterizing prediabetes phenotypes may be useful in guiding diabetes prevention efforts; however, heterogeneous criteria to define prediabetes have led to inconsistent prevalence estimates, particularly in low- and middle-income countries. We estimated trends in untreated prediabetes prevalence in Mexico across different definitions and its association with prevalent cardiometabolic conditions. METHODS We conducted a serial cross-sectional analysis of National Health and Nutrition Surveys in Mexico (2016-2021), totaling 21,442 Mexican adults, excluding individuals with diagnosed or undiagnosed diabetes. Prediabetes was defined using ADA (impaired fasting glucose [IFG] 100-125 mg/dL and/or HbA1c 5.7-6.4%), WHO (IFG 110-125 mg/dL), and IEC criteria (HbA1c 6.0-6.4%). Prevalence trends of prediabetes over time were evaluated using Poisson regression and its association with prevalent cardiometabolic conditions with logistic regression. RESULTS Prevalence of prediabetes in Mexico in 2021 was 27.3%. Despite an overall downward trend in prediabetes (RR 0.960, 95%CI 0.940-0.979), this decrease was primarily driven by decreases in prediabetes by ADA-IFG (RR 0.883, 95%CI 0.861-0.907) and WHO-IFG criteria (RR 0.878, 95%CI 0.838-0.921), while prediabetes by ADA-HbA1c (RR 1.049, 95%CI 1.022-1.077) and IEC-HbA1C criteria (RR 1.064, 95%CI 1.014-1.115) increased over time. Prediabetes prevalence increased over time in adults >40 years, individuals with central obesity, self-identified as indigenous or living in urban areas. Regardless of the definition, prediabetes was associated with increased risk of cardiometabolic conditions. CONCLUSIONS Prediabetes rates in Mexico from 2016-2021 varied based on defining criteria but consistently increased for HbA1c-based definitions and high-risk subgroups. Regardless of the definition, prediabetes clusters subjects with high cardiometabolic risk.
- Open Access
Insulin resistance potentiates the effect of remnant cholesterol on cardiovascular mortality in individuals without diabetes
BACKGROUND: Remnant cholesterol (RC) and insulin resistance (IR) have been independently associated with cardiovascular risk. OBJECTIVES: We evaluated the mediating role of IR in the risk conferred by RC on atherosclerotic cardiovascular disease (ASCVD) mortality. METHODS: Analysis of the National Health and Nutrition Examination Survey (NHANES-III/IV), including 16,201 individuals ≥20 years without diabetes and with complete mortality data. RC levels were calculated using total cholesterol, non-HDL-c, and LDL-c estimated with Sampson’s formula; IR was defined as HOMA2-IR≥2.5 and ASCVD mortality as a composite of cardiovascular and cerebrovascular mortality. Multiple linear regression was used to assess the relationship between HOMA2-IR and RC and competing-risk models to assess their joint role in ASCVD mortality. Causally ordered mediation models were used to explore the mediating role of IR in RC-associated ASCVD mortality. RESULTS: We identified an association between higher HOMA2-IR and higher RC levels. The effect of IR on ASCVD mortality was predominant (sHR 1.68, 95%CI 1.42-1.98) and decreased at older ages (sHR 0.993, 95%CI 0.991-0.995) compared to RC (sHR 0.965, 95%CI 0.826-1.126). Higher risk of ASCVD mortality was observed in individuals with IR but normal RC (sHR 1.19, 95%CI 1.01-1.41) and subjects with IR and high RC (sHR 1.27, 95%CI 1.07-1.50), but not in subjects without IR but high RC. In mediation models, HOMA2-IR accounted for 86.5% (95%CI 78.8-100.0) of the effect of RC levels on ASCVD mortality. CONCLUSIONS: Our findings suggest that RC potentiates the risk of ASCVD mortality through its effect on whole-body insulin sensitivity, particularly among younger individuals. CONDENSED This study aimed to assess the role of insulin resistance (IR) in the association between remnant cholesterol (RC) and atherosclerotic cardiovascular disease (ASCVD) mortality. Using data from NHANES-III/IV, the study found that the effect of IR on ASCVD mortality was predominant compared to RC. Individuals with IR but normal RC or IR with elevated RC had higher risk of ASCVD mortality compared to subjects with elevated RC without IR. Overall, IR accounted for 86.5% of the effect of RC on ASCVD mortality. RC increases the risk of ASCVD mortality through its effect on insulin sensitivity, particularly among younger individuals. PERSPECTIVES: COMPETENCY IN PATIENT CARE AND PROCEDURAL SKILLS: In patients with elevated remnant cholesterol, insulin resistance potentiates its effect on atherosclerotic cardiovascular disease mortality. TRANSLATIONAL OUTLOOK: Additional research from randomized clinical trials is needed to evaluate whether concomitant therapies to improve insulin sensitivity in patients with residual cardiovascular risk may provide an additional benefit in reducing cardiovascular disease burden and mortality. GRAPHICAL ABSTRACT – CENTRAL IMAGE:
Open AccessInsulin resistance potentiates the effect of remnant cholesterol on cardiovascular mortality in individuals without diabetes
BACKGROUND: Remnant cholesterol (RC) and insulin resistance (IR) have been independently associated with cardiovascular risk. OBJECTIVES: We evaluated the mediating role of IR in the risk conferred by RC on atherosclerotic cardiovascular disease (ASCVD) mortality. METHODS: Analysis of the National Health and Nutrition Examination Survey (NHANES-III/IV), including 16,201 individuals ≥20 years without diabetes and with complete mortality data. RC levels were calculated using total cholesterol, non-HDL-c, and LDL-c estimated with Sampson’s formula; IR was defined as HOMA2-IR≥2.5 and ASCVD mortality as a composite of cardiovascular and cerebrovascular mortality. Multiple linear regression was used to assess the relationship between HOMA2-IR and RC and competing-risk models to assess their joint role in ASCVD mortality. Causally ordered mediation models were used to explore the mediating role of IR in RC-associated ASCVD mortality. RESULTS: We identified an association between higher HOMA2-IR and higher RC levels. The effect of IR on ASCVD mortality was predominant (sHR 1.68, 95%CI 1.42-1.98) and decreased at older ages (sHR 0.993, 95%CI 0.991-0.995) compared to RC (sHR 0.965, 95%CI 0.826-1.126). Higher risk of ASCVD mortality was observed in individuals with IR but normal RC (sHR 1.19, 95%CI 1.01-1.41) and subjects with IR and high RC (sHR 1.27, 95%CI 1.07-1.50), but not in subjects without IR but high RC. In mediation models, HOMA2-IR accounted for 86.5% (95%CI 78.8-100.0) of the effect of RC levels on ASCVD mortality. CONCLUSIONS: Our findings suggest that RC potentiates the risk of ASCVD mortality through its effect on whole-body insulin sensitivity, particularly among younger individuals. CONDENSED This study aimed to assess the role of insulin resistance (IR) in the association between remnant cholesterol (RC) and atherosclerotic cardiovascular disease (ASCVD) mortality. Using data from NHANES-III/IV, the study found that the effect of IR on ASCVD mortality was predominant compared to RC. Individuals with IR but normal RC or IR with elevated RC had higher risk of ASCVD mortality compared to subjects with elevated RC without IR. Overall, IR accounted for 86.5% of the effect of RC on ASCVD mortality. RC increases the risk of ASCVD mortality through its effect on insulin sensitivity, particularly among younger individuals. PERSPECTIVES: COMPETENCY IN PATIENT CARE AND PROCEDURAL SKILLS: In patients with elevated remnant cholesterol, insulin resistance potentiates its effect on atherosclerotic cardiovascular disease mortality. TRANSLATIONAL OUTLOOK: Additional research from randomized clinical trials is needed to evaluate whether concomitant therapies to improve insulin sensitivity in patients with residual cardiovascular risk may provide an additional benefit in reducing cardiovascular disease burden and mortality. GRAPHICAL ABSTRACT – CENTRAL IMAGE:
- Open Access
- 29 September 2022
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 51 (6) , 1711-1721
Socio-demographic inequalities and excess non-COVID-19 mortality during the COVID-19 pandemic: a data-driven analysis of 1 069 174 death certificates in Mexico
Background: In 2020, Mexico experienced one of the highest rates of excess mortality globally. However, the extent of non-COVID deaths on excess mortality, its regional distribution and the association between socio-demographic inequalities have not been characterized. Methods: We conducted a retrospective municipal and individual-level study using 1 069 174 death certificates to analyse COVID-19 and non-COVID-19 deaths classified by ICD-10 codes. Excess mortality was estimated as the increase in cause-specific mortality in 2020 compared with the average of 2015–2019, disaggregated by primary cause of death, death setting (in-hospital and out-of-hospital) and geographical location. Correlates of individual and municipal non-COVID-19 mortality were assessed using mixed effects logistic regression and negative binomial regression models, respectively. Results: We identified a 51% higher mortality rate (276.11 deaths per 100 000 inhabitants) compared with the 2015–2019 average period, largely attributable to COVID-19. Non-COVID-19 causes comprised one-fifth of excess deaths, with acute myocardial infarction and type 2 diabetes as the two leading non-COVID-19 causes of excess mortality. COVID-19 deaths occurred primarily in-hospital, whereas excess non-COVID-19 deaths occurred in out-of-hospital settings. Municipal-level predictors of non-COVID-19 excess mortality included levels of social security coverage, higher rates of COVID-19 hospitalization and social marginalization. At the individual level, lower educational attainment, blue-collar employment and lack of medical care assistance prior to death were associated with non-COVID-19 deaths. Conclusion: Non-COVID-19 causes of death, largely chronic cardiometabolic conditions, comprised up to one-fifth of excess deaths in Mexico during 2020. Non-COVID-19 excess deaths occurred disproportionately out-of-hospital and were associated with both individual- and municipal-level socio-demographic inequalities.
- 29 September 2022
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 51 (6) , 1711-1721
Open AccessSocio-demographic inequalities and excess non-COVID-19 mortality during the COVID-19 pandemic: a data-driven analysis of 1 069 174 death certificates in Mexico
Background: In 2020, Mexico experienced one of the highest rates of excess mortality globally. However, the extent of non-COVID deaths on excess mortality, its regional distribution and the association between socio-demographic inequalities have not been characterized. Methods: We conducted a retrospective municipal and individual-level study using 1 069 174 death certificates to analyse COVID-19 and non-COVID-19 deaths classified by ICD-10 codes. Excess mortality was estimated as the increase in cause-specific mortality in 2020 compared with the average of 2015–2019, disaggregated by primary cause of death, death setting (in-hospital and out-of-hospital) and geographical location. Correlates of individual and municipal non-COVID-19 mortality were assessed using mixed effects logistic regression and negative binomial regression models, respectively. Results: We identified a 51% higher mortality rate (276.11 deaths per 100 000 inhabitants) compared with the 2015–2019 average period, largely attributable to COVID-19. Non-COVID-19 causes comprised one-fifth of excess deaths, with acute myocardial infarction and type 2 diabetes as the two leading non-COVID-19 causes of excess mortality. COVID-19 deaths occurred primarily in-hospital, whereas excess non-COVID-19 deaths occurred in out-of-hospital settings. Municipal-level predictors of non-COVID-19 excess mortality included levels of social security coverage, higher rates of COVID-19 hospitalization and social marginalization. At the individual level, lower educational attainment, blue-collar employment and lack of medical care assistance prior to death were associated with non-COVID-19 deaths. Conclusion: Non-COVID-19 causes of death, largely chronic cardiometabolic conditions, comprised up to one-fifth of excess deaths in Mexico during 2020. Non-COVID-19 excess deaths occurred disproportionately out-of-hospital and were associated with both individual- and municipal-level socio-demographic inequalities.
- Open Access
Clinical prediction models for mortality in patients with covid-19: external validation and individual participant data meta-analysis
Objective: To externally validate various prognostic models and scoring rules for predicting short term mortality in patients admitted to hospital for covid-19. Design: Two stage individual participant data meta-analysis. Setting: Secondary and tertiary care. Participants: 46 914 patients across 18 countries, admitted to a hospital with polymerase chain reaction confirmed covid-19 from November 2019 to April 2021. Data sources: Multiple (clustered) cohorts in Brazil, Belgium, China, Czech Republic, Egypt, France, Iran, Israel, Italy, Mexico, Netherlands, Portugal, Russia, Saudi Arabia, Spain, Sweden, United Kingdom, and United States previously identified by a living systematic review of covid-19 prediction models published in The BMJ , and through PROSPERO, reference checking, and expert knowledge. Model selection and eligibility criteria: Prognostic models identified by the living systematic review and through contacting experts. A priori models were excluded that had a high risk of bias in the participant domain of PROBAST (prediction model study risk of bias assessment tool) or for which the applicability was deemed poor. Methods: Eight prognostic models with diverse predictors were identified and validated. A two stage individual participant data meta-analysis was performed of the estimated model concordance (C) statistic, calibration slope, calibration-in-the-large, and observed to expected ratio (O:E) across the included clusters. Main outcome measures: 30 day mortality or in-hospital mortality. Results: Datasets included 27 clusters from 18 different countries and contained data on 46 914patients. The pooled estimates ranged from 0.67 to 0.80 (C statistic), 0.22 to 1.22 (calibration slope), and 0.18 to 2.59 (O:E ratio) and were prone to substantial between study heterogeneity. The 4C Mortality Score by Knight et al (pooled C statistic 0.80, 95% confidence interval 0.75 to 0.84, 95% prediction interval 0.72 to 0.86) and clinical model by Wang et al (0.77, 0.73 to 0.80, 0.63 to 0.87) had the highest discriminative ability. On average, 29% fewer deaths were observed than predicted by the 4C Mortality Score (pooled O:E 0.71, 95% confidence interval 0.45 to 1.11, 95% prediction interval 0.21 to 2.39), 35% fewer than predicted by the Wang clinical model (0.65, 0.52 to 0.82, 0.23 to 1.89), and 4% fewer than predicted by Xie et al’s model (0.96, 0.59 to 1.55, 0.21 to 4.28). Conclusion: The prognostic value of the included models varied greatly between the data sources. Although the Knight 4C Mortality Score and Wang clinical model appeared most promising, recalibration (intercept and slope updates) is needed before implementation in routine care.
Open AccessClinical prediction models for mortality in patients with covid-19: external validation and individual participant data meta-analysis
Objective: To externally validate various prognostic models and scoring rules for predicting short term mortality in patients admitted to hospital for covid-19. Design: Two stage individual participant data meta-analysis. Setting: Secondary and tertiary care. Participants: 46 914 patients across 18 countries, admitted to a hospital with polymerase chain reaction confirmed covid-19 from November 2019 to April 2021. Data sources: Multiple (clustered) cohorts in Brazil, Belgium, China, Czech Republic, Egypt, France, Iran, Israel, Italy, Mexico, Netherlands, Portugal, Russia, Saudi Arabia, Spain, Sweden, United Kingdom, and United States previously identified by a living systematic review of covid-19 prediction models published in The BMJ , and through PROSPERO, reference checking, and expert knowledge. Model selection and eligibility criteria: Prognostic models identified by the living systematic review and through contacting experts. A priori models were excluded that had a high risk of bias in the participant domain of PROBAST (prediction model study risk of bias assessment tool) or for which the applicability was deemed poor. Methods: Eight prognostic models with diverse predictors were identified and validated. A two stage individual participant data meta-analysis was performed of the estimated model concordance (C) statistic, calibration slope, calibration-in-the-large, and observed to expected ratio (O:E) across the included clusters. Main outcome measures: 30 day mortality or in-hospital mortality. Results: Datasets included 27 clusters from 18 different countries and contained data on 46 914patients. The pooled estimates ranged from 0.67 to 0.80 (C statistic), 0.22 to 1.22 (calibration slope), and 0.18 to 2.59 (O:E ratio) and were prone to substantial between study heterogeneity. The 4C Mortality Score by Knight et al (pooled C statistic 0.80, 95% confidence interval 0.75 to 0.84, 95% prediction interval 0.72 to 0.86) and clinical model by Wang et al (0.77, 0.73 to 0.80, 0.63 to 0.87) had the highest discriminative ability. On average, 29% fewer deaths were observed than predicted by the 4C Mortality Score (pooled O:E 0.71, 95% confidence interval 0.45 to 1.11, 95% prediction interval 0.21 to 2.39), 35% fewer than predicted by the Wang clinical model (0.65, 0.52 to 0.82, 0.23 to 1.89), and 4% fewer than predicted by Xie et al’s model (0.96, 0.59 to 1.55, 0.21 to 4.28). Conclusion: The prognostic value of the included models varied greatly between the data sources. Although the Knight 4C Mortality Score and Wang clinical model appeared most promising, recalibration (intercept and slope updates) is needed before implementation in routine care.
- Open Access
Sociodemographic inequalities and excess non-COVID-19 mortality during the COVID-19 pandemic: A data-driven analysis of 1,069,174 death certificates in Mexico
BACKGROUND In 2020, Mexico experienced one of the highest rates of excess mortality globally. However, the extent to which non-COVID deaths contributed to excess mortality, its regional characterization, and the association between municipal-and individual-level sociodemographic inequality has not been characterized. METHODS We conducted a retrospective municipal an individual-level study using death certificate data in Mexico from 2016-2020. We analyzed mortality related to COVID-19 and to non-COVID-19 causes using ICD-10 codes to identify cause-specific mortality. Excess mortality was estimated as the increase in deaths in 2020 compared to the average of 2016-2019, disaggregated by primary cause of death, death setting (in-hospital and out-of-hospital) and geographical location. We evaluated correlates of non-COVID-19 mortality at the individual level using mixed effects logistic regression and correlates of non-COVID-19 excess mortality in 2020 at the municipal level using negative binomial regression. RESULTS We identified 1,069,174 deaths in 2020 (833.5 per 100,000 inhabitants), which was 49% higher compared to the 2016-2019 average (557.38 per 100,000 inhabitants). Overall excess mortality (276.11 deaths per 100,000 inhabitants) was attributable in 76.1% to COVID-19; however, non-COVID-19 causes comprised one-fifth of excess deaths. COVID-19 deaths occurred primarily in-hospital, while excess non-COVID-19 deaths decreased in this setting and increased out-of-hospital. Excess non-COVID-19 mortality displayed geographical heterogeneity linked to sociodemographic inequalities with clustering in states in southern Mexico. Municipal-level predictors of non-COVID-19 excess mortality included levels of social security coverage, higher rates of COVID-19 hospitalization, and social marginalization. At the individual level, lower educational attainment, blue collar workers, and lack of medical care assistance were associated with non-COVID-19 mortality during 2020. CONCLUSION Non-COVID-19 causes of death, largely chronic cardiometabolic conditions, comprised up to one-fifth of excess deaths in Mexico during 2020. Non-COVID-19 excess deaths occurred disproportionately out-of-hospital and were associated with both individual-and municipal-level sociodemographic inequalities. These findings should prompt an urgent call to action to improve healthcare coverage and access to reduce health and sociodemographic inequalities in Mexico to reduce preventable mortality in situations which increase the stress of healthcare systems, including the ongoing COVID-19 pandemic.
Open AccessSociodemographic inequalities and excess non-COVID-19 mortality during the COVID-19 pandemic: A data-driven analysis of 1,069,174 death certificates in Mexico
BACKGROUND In 2020, Mexico experienced one of the highest rates of excess mortality globally. However, the extent to which non-COVID deaths contributed to excess mortality, its regional characterization, and the association between municipal-and individual-level sociodemographic inequality has not been characterized. METHODS We conducted a retrospective municipal an individual-level study using death certificate data in Mexico from 2016-2020. We analyzed mortality related to COVID-19 and to non-COVID-19 causes using ICD-10 codes to identify cause-specific mortality. Excess mortality was estimated as the increase in deaths in 2020 compared to the average of 2016-2019, disaggregated by primary cause of death, death setting (in-hospital and out-of-hospital) and geographical location. We evaluated correlates of non-COVID-19 mortality at the individual level using mixed effects logistic regression and correlates of non-COVID-19 excess mortality in 2020 at the municipal level using negative binomial regression. RESULTS We identified 1,069,174 deaths in 2020 (833.5 per 100,000 inhabitants), which was 49% higher compared to the 2016-2019 average (557.38 per 100,000 inhabitants). Overall excess mortality (276.11 deaths per 100,000 inhabitants) was attributable in 76.1% to COVID-19; however, non-COVID-19 causes comprised one-fifth of excess deaths. COVID-19 deaths occurred primarily in-hospital, while excess non-COVID-19 deaths decreased in this setting and increased out-of-hospital. Excess non-COVID-19 mortality displayed geographical heterogeneity linked to sociodemographic inequalities with clustering in states in southern Mexico. Municipal-level predictors of non-COVID-19 excess mortality included levels of social security coverage, higher rates of COVID-19 hospitalization, and social marginalization. At the individual level, lower educational attainment, blue collar workers, and lack of medical care assistance were associated with non-COVID-19 mortality during 2020. CONCLUSION Non-COVID-19 causes of death, largely chronic cardiometabolic conditions, comprised up to one-fifth of excess deaths in Mexico during 2020. Non-COVID-19 excess deaths occurred disproportionately out-of-hospital and were associated with both individual-and municipal-level sociodemographic inequalities. These findings should prompt an urgent call to action to improve healthcare coverage and access to reduce health and sociodemographic inequalities in Mexico to reduce preventable mortality in situations which increase the stress of healthcare systems, including the ongoing COVID-19 pandemic.
- Open Access
Effectiveness of a nation-wide COVID-19 vaccination program in Mexico
BACKGROUND: Vaccination has been effective in ameliorating the impact of COVID-19. However, estimation of vaccine effectiveness (VE) is still unavailable for some widely used vaccines and underrepresented groups. Here, we report on the effectiveness of a nation-wide COVID-19 vaccination program in Mexico. METHODS: We used a test-negative design within a national COVID-19 surveillance system to assess VE of the BNT162b2, mRNA-12732, Gam-COVID-Vac, Ad5-nCoV, Ad26.COV2.S, ChAdOx1 and CoronaVac vaccines, against SARS-CoV-2 infection, COVID-19 related hospitalization and death for adults ≥18 years in Mexico. VE was estimated using Cox proportional hazard models considering time-varying vaccination status in partial and fully vaccinated individuals compared to unvaccinated adults, adjusted by age, sex, comorbidities and municipality. We also estimated VE for adults ≥60 years, for cases with diabetes and comparing periods with predominance of variants B.1.1.519 and B.1.617.2. RESULTS: We assessed 793,487 vaccinated compared to 4,792,338 unvaccinated adults between December 24 th , 2020, and September 27 th , 2021. VE against SARS-CoV-2 infection was highest for fully vaccinated individuals with mRNA-12732 (91.5%, 95%CI 90.3-92.4) and Ad26.COV2.S (82.2%, 95%CI 81.4-82.9), whereas for COVID-19 related hospitalization were BNT162b2 (84.3%, 95%CI 83.6-84.9) and Gam-COVID-Vac (81.4% 95%CI 79.5-83.1) and for mortality BNT162b2 (89.8%, 95%CI 89.2-90.2) and mRNA-12732 (93.5%, 95%CI 86.0-97.0). VE for all evaluated vaccines was reduced for adults ≥60 years, people with diabetes, and in periods of Delta variant predominance. CONCLUSIONS: All evaluated vaccines were effective against SARS-CoV-2 infection and COVID-19 related hospitalization and death. Mass vaccination campaigns with multiple vaccine products are feasible and effective to maximize vaccination coverage.
Open AccessEffectiveness of a nation-wide COVID-19 vaccination program in Mexico
BACKGROUND: Vaccination has been effective in ameliorating the impact of COVID-19. However, estimation of vaccine effectiveness (VE) is still unavailable for some widely used vaccines and underrepresented groups. Here, we report on the effectiveness of a nation-wide COVID-19 vaccination program in Mexico. METHODS: We used a test-negative design within a national COVID-19 surveillance system to assess VE of the BNT162b2, mRNA-12732, Gam-COVID-Vac, Ad5-nCoV, Ad26.COV2.S, ChAdOx1 and CoronaVac vaccines, against SARS-CoV-2 infection, COVID-19 related hospitalization and death for adults ≥18 years in Mexico. VE was estimated using Cox proportional hazard models considering time-varying vaccination status in partial and fully vaccinated individuals compared to unvaccinated adults, adjusted by age, sex, comorbidities and municipality. We also estimated VE for adults ≥60 years, for cases with diabetes and comparing periods with predominance of variants B.1.1.519 and B.1.617.2. RESULTS: We assessed 793,487 vaccinated compared to 4,792,338 unvaccinated adults between December 24 th , 2020, and September 27 th , 2021. VE against SARS-CoV-2 infection was highest for fully vaccinated individuals with mRNA-12732 (91.5%, 95%CI 90.3-92.4) and Ad26.COV2.S (82.2%, 95%CI 81.4-82.9), whereas for COVID-19 related hospitalization were BNT162b2 (84.3%, 95%CI 83.6-84.9) and Gam-COVID-Vac (81.4% 95%CI 79.5-83.1) and for mortality BNT162b2 (89.8%, 95%CI 89.2-90.2) and mRNA-12732 (93.5%, 95%CI 86.0-97.0). VE for all evaluated vaccines was reduced for adults ≥60 years, people with diabetes, and in periods of Delta variant predominance. CONCLUSIONS: All evaluated vaccines were effective against SARS-CoV-2 infection and COVID-19 related hospitalization and death. Mass vaccination campaigns with multiple vaccine products are feasible and effective to maximize vaccination coverage.